--- title: "Callan Jmb | 8-K: FY2025 Revenue: USD 5.723 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/281237033.md" datetime: "2026-03-31T20:13:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281237033.md) - [en](https://longbridge.com/en/news/281237033.md) - [zh-HK](https://longbridge.com/zh-HK/news/281237033.md) --- # Callan Jmb | 8-K: FY2025 Revenue: USD 5.723 M Revenue: As of FY2025, the actual value is USD 5.723 M. EPS: As of FY2025, the actual value is USD -1.82. EBIT: As of FY2025, the actual value is USD -7.041 M. ### Financial Highlights for the Full Year Ended December 31, 2025 vs. 2024 #### Revenue - Revenue for 2025 was $5.7 million, a decrease of $0.9 million from $6.6 million in 2024, primarily due to decreased demand for emergency preparedness services by certain states and local governments . #### Cost of Revenues - Cost of revenues decreased by $0.4 million to $3.6 million in 2025 from $4 million in 2024, mainly attributed to the decrease in revenue . #### Gross Profit - Gross profit decreased by $0.5 million, from $2.6 million in 2024 to $2.1 million in 2025 . #### Selling, General and Administrative (SG&A) Expenses - SG&A expenses increased by $3.8 million to $8.6 million in 2025 from $4.8 million in 2024, driven by professional fees for the Company’s initial public offering, becoming a public entity, and increased information technology support costs . #### Impairment Loss on Property and Equipment - Callan JMB Inc. reported an impairment loss of $542,088 in 2025, compared to $0 in 2024 . #### Loss from Operations - Loss from operations was - $7.0 million in 2025, an increase from - $2.3 million in 2024 . #### Net Loss - Net loss for 2025 was - $7,966,366, compared to - $2,293,648 in 2024 . #### Cash and Cash Equivalents - Cash and cash equivalents were $2,130,758 as of December 31, 2025, a slight increase from $2,097,945 as of December 31, 2024 . #### Net Cash Flow from Operating Activities - Net cash flow from operating activities was - $4,546,724 in 2025, a decrease from $540,353 in 2024 . #### Net Cash Flow from Investing Activities - Net cash flow from investing activities was - $616,896 in 2025, compared to - $46,167 in 2024 . #### Net Cash Flow from Financing Activities - Net cash flow from financing activities was $5,196,433 in 2025, an increase from - $3,551,861 in 2024 . ### Operational Metrics and Business Highlights - Callan JMB Inc. signed a manufacturing oversight, federal deployment, and commercialization agreement with Biostax Corp d/b/a Attune Biotech Inc. . - The Company established a joint venture with Revival Health to integrate logistics, shipping systems, bioservices, and data infrastructure . - Callan JMB Services (India) Private Limited was launched with plans for a temperature-controlled warehouse in Pune, Maharashtra, for pharmaceutical storage and distribution . - An agreement was secured with Walker’s Pharmaceuticals Ltd., and work is ongoing with other Indian companies to facilitate U.S. market entry and manufacturing plant establishment . - A preliminary agreement was made with an oral drug delivery system maker to install manufacturing equipment in Callan JMB Inc.’s cGMP facility in Texas . - The emergency preparedness contract with the City of Chicago was extended through June 2026, including a $1.5 million funding increase, raising the total contract value to $9.1 million . - Callan JMB Inc. was awarded a second five-year contract by the Oregon Health Authority (OHA) for medical emergency preparedness and response services . - The Company supported Texas and New Mexico in their measles outbreak response by redistributing MMR II vaccine doses from Chicago . - A new comprehensive lease program for vaccine management was announced . - Immunizations were successfully administered across 44 Tennessee counties through a partnership with Health Hero Tennessee . - Callan JMB Inc. entered the food sampling sector by expanding its reclamation operations . - The proprietary Sentry Monitoring System was upgraded from Java to HTML5 . ### Outlook - Callan JMB Inc. is focused on strengthening its core infrastructure, scaling readiness capabilities, and advancing strategic growth initiatives in high-velocity sectors like healthcare and food logistics for the remainder of 2026 . The Company is committed to long-term shareholder value creation by building a resilient, mission-driven organization . This organization aims to be positioned at the center of critical healthcare and national preparedness supply chains . ### Related Stocks - [CJMB.US](https://longbridge.com/en/quote/CJMB.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Home Depot Was Once My Greatest Investment, But Now It's a Flaming Mess](https://longbridge.com/en/news/286951517.md) - [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md) - [FS KKR Capital to post investor presentations on website after market close](https://longbridge.com/en/news/286815114.md) - [Is Nvidia spending its cash on the right things? Investors will soon get an update.](https://longbridge.com/en/news/286948142.md)